The influence of metabolic factors for nonalcoholic fatty liver disease in women

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Chung, Goh Eun ^a   Yim, Jeong Yoon ^a   Kim, Donghee ^a   Lim, Seon Hee ^a   Yang, Jong In ^a   Kim, Young Sun ^a   Yang, Sun Young ^a   Kwak, Min Sun ^a   Kim, Joo Sung ^a   Cho, Sang Heon ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; POSTMENOPAUSE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; ABDOMEN; BLOOD; BODY MASS; DIAGNOSTIC IMAGING; HYPOALPHALIPOPROTEINEMIA; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREMENOPAUSE;

ABDOMEN; ADULT; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; HYPOALPHALIPOPROTEINEMIAS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS; TRIGLYCERIDES; ULTRASONOGRAPHY;

EID: 84929379937     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/131528     Document Type: Article

References (42)

1. G. Vernon, A. Baranova, and Z. M. Younossi, "Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults," Alimentary Pharmacology and Therapeutics, vol. 34, no. 3, pp. 274-285, 2011.
2. D. M. Torres, C. D. Williams, and S. A. Harrison, "Features, diagnosis, and treatment of nonalcoholic fatty liver disease," Clinical Gastroenterology and Hepatology, vol. 10, no. 8, pp. 837-858, 2012.
3. J. M. Clark, "The epidemiology of nonalcoholic fatty liver disease in adults," Journal of Clinical Gastroenterology, vol. 40, supplement 1, pp. S5-S10, 2006.
4. G. Marchesini, M. Brizi, G. Blanchi et al., "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome," Diabetes, vol. 50, no. 8, pp. 1844-1850, 2001.
5. G. Pagano, G. Pacini, G. Musso et al., "Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association," Hepatology, vol. 35, no. 2, pp. 367-372, 2002.
6. G. Marchesini, E. Bugianesi, G. Forlani et al., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome," Hepatology, vol. 37, no. 4, pp. 917-923, 2003.
7. J. C. Lovejoy, C. M. Champagne, L. de Jonge, H. Xie, and S. R. Smith, "Increased visceral fat and decreased energy expenditure during the menopausal transition," International Journal of Obesity, vol. 32, no. 6, pp. 949-958, 2008.
8. A. Suzuki and M. F. Abdelmalek, "Nonalcoholic fatty liver disease in women," Women's Health, vol. 5, no. 2, pp. 191-203, 2009.
9. H. Völzke, S. Schwarz, S. E. Baumeister et al., "Menopausal status and hepatic steatosis in a general female population," Gut, vol. 56, no. 4, pp. 594-595, 2007.
10. S. H. Park, W. K. Jeon, S. H. Kim et al., "Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults," Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 138-143, 2006.
11. J. D. Yang, M. F. Abdelmalek, H. Pang et al., "Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis," Hepatology, vol. 59, no. 4, pp. 1406-1414, 2014.
12. Y. Gutierrez-Grobe, G. Ponciano-Rodríguez, M. H. Ramos, M. Uribe, and N. Méndez-Sánchez, "Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women.The role of estrogens," Annals of Hepatology, vol. 9, no. 4, pp. 402-409, 2010.
13. J.McKenzie, B. M. Fisher, A. J. Jaap, A. Stanley, K. Paterson, and N. Sattar, "Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial," Clinical Endocrinology, vol. 65, no. 1, pp. 40-44, 2006.
14. P.W. F.Wilson, R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel, "Prediction of coronary heart disease using risk factor categories," Circulation, vol. 97, no. 18, pp. 1837-1847, 1998.
15. "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),"TheJournal of the AmericanMedical Association, vol. 285, no. 19, pp. 2486-2497, 2001.
16. S.-Y. Choi, D. Kim, H. J. Kim et al., "The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans," The American Journal of Gastroenterology, vol. 104, no. 8, pp. 1953-1960, 2009.
17. M.Hamaguchi, T.Kojima, A. Ohbora,N. Takeda, M. Fukui, and T. Kato, "Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women," World Journal of Gastroenterology, vol. 18, no. 3, pp. 237-243, 2012.
18. J. C. Bae, Y. K. Cho,W. Y. Lee et al., "Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects," The American Journal of Gastroenterology, vol. 105, no. 11, pp. 2389-2395, 2010.
19. S. de Souza Bruno, M. H. Rodrigues, M. C. B. Alvares, J. Nahas-Neto, and E. A. P. Nahas, "Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women," Climacteric, vol. 17, no. 4, pp. 465-471, 2014.
20. G. Tarantino, G. Saldalamacchia, P. Conca, andA.Arena, "Nonalcoholic fatty liver disease: further expression of the metabolic syndrome," Journal of Gastroenterology and Hepatology, vol. 22, no. 3, pp. 293-303, 2007.
21. J. B. Dixon, P. S. Bhathal, and P. E. O'Brien, "Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese," Gastroenterology, vol. 121, no. 1, pp. 91-100, 2001.
22. Z.-W. Chen, L.-Y. Chen, H.-L. Dai, J.-H. Chen, and L.-Z. Fang, "Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease," Journal of Zhejiang University: Science B, vol. 9, no. 8, pp. 616-622, 2008.
23. Y. Eguchi, T. Eguchi, T.Mizuta et al., "Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease," Journal of Gastroenterology, vol. 41, no. 5, pp. 462-469, 2006.
24. B. J. Park, Y. J. Kim, D. H. Kim et al., "Visceral adipose tissue area is an independent risk factor for hepatic steatosis," Journal of Gastroenterology and Hepatology, vol. 23, no. 6, pp. 900-907, 2008.
25. M. E. E. Jones, A. W. Thorburn, K. L. Britt et al., "Aromatasedeficient (ArKO) mice have a phenotype of increased adiposity," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12735-12740, 2000.
26. K. N. Hewitt, W. C. Boon, Y. Murata, M. E. E. Jones, and E. R. Simpson, "The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis," Endocrinology, vol. 144, no. 9, pp. 3895-3903, 2003.
27. Y. Nemoto, K. Toda, M. Ono et al., "Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice," The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1819-1825, 2000.
28. M. van Hoof, J. Rahier, and Y. Horsmans, "Tamoxifen-induced steatohepatitis," Annals of Internal Medicine, vol. 124, no. 9, pp. 855-856, 1996.
29. K. A. Oien, D. Moffat, G. W. Curry et al., "Cirrhosis with steatohepatitis after adjuvant tamoxifen," The Lancet, vol. 353, no. 9146, pp. 36-37, 1999.
30. S. Bruno, P. Maisonneuve, P. Castellana et al., "Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial,"TheBritishMedical Journal, vol. 330, no. 7497, pp. 932-937, 2005.
31. J. I. Torréns,K. Sutton-Tyrrell, X. Zhao et al., "Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation," Menopause, vol. 16, no. 2, pp. 257-264, 2009.
32. G. D. Braunstein, "Androgen insufficiency in women: summary of critical issues," Fertility and Sterility, vol. 77, supplement 4,pp. S94-S99, 2002.
33. K.H.Polderman,L. J.G.Gooren,H. Asscheman, A. Bakker, and R. J. Heine, "Induction of insulin resistance by androgens and estrogens," The Journal of Clinical Endocrinology &Metabolism, vol. 79, no. 1, pp. 265-271, 1994.
34. D. Grady, D. Herrington, V. Bittner et al., "Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II)," The Journal of the American Medical Association, vol. 288, no. 1, pp. 49-57, 2002.
35. J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial," The Journal of the American Medical Association, vol. 288, pp. 321-333, 2002.
36. G. L. Anderson, M. Limacher, A. R. Assaf et al., "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial," The Journal of the American Medical Association, vol. 291, no. 14, pp. 1701-1712, 2004.
37. F. Sun, I. J. Norman, and A. E.While, "Physical activity in older people: a systematic review," BMC Public Health, vol. 13, no. 1, article 449, 2013.
38. R. J.Valentine, M. M.Misic, K. S. Rosengren, J. A.Woods, and E. M. Evans, "Sex impacts the relation between body composition and physical function in older adults," Menopause, vol. 16, no. 3, pp. 518-523, 2009.
39. L. Codes, T. Asselah, D. Cazals-Hatem et al., "Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy," Gut, vol. 56, no. 3, pp. 390-395, 2007.
40. A. J. Sanyal, "AGA technical review on nonalcoholic fatty liver disease," Gastroenterology, vol. 123, no. 5, pp. 1705-1725, 2002.
41. N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology," Gastroenterology, vol. 142, pp. 1592-1609, 2012.
42. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines: management of nonalcoholic fatty liver disease," Clinical and Molecular Hepatology, vol. 19, pp. 325-348, 2013.